Last reviewed · How we verify

Brivaracetam Film-coated tablet — Competitive Intelligence Brief

Brivaracetam Film-coated tablet (Brivaracetam Film-coated tablet) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiepileptic agent (SV2A ligand). Area: Neurology.

phase 3 Antiepileptic agent (SV2A ligand) SV2A (synaptic vesicle protein 2A) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Brivaracetam Film-coated tablet (Brivaracetam Film-coated tablet) — UCB Biopharma SRL. Brivaracetam binds to synaptic vesicle protein 2A (SV2A) in the brain to reduce neuronal excitability and prevent seizures.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Brivaracetam Film-coated tablet TARGET Brivaracetam Film-coated tablet UCB Biopharma SRL phase 3 Antiepileptic agent (SV2A ligand) SV2A (synaptic vesicle protein 2A)
Brivaracetam infusion Brivaracetam infusion UCB Pharma phase 3 Antiepileptic agent (SV2A ligand) SV2A (synaptic vesicle protein 2A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiepileptic agent (SV2A ligand) class)

  1. UCB Biopharma SRL · 1 drug in this class
  2. UCB Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brivaracetam Film-coated tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/brivaracetam-film-coated-tablet. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: